Amylyx Pharmaceuticals' (AMLX) Relyvrio Receives Approval from FDA

(Updated - September 29, 2022 4:47 PM EDT)

Amylyx Pharmaceuticals' (NASDAQ: AMLX) Relyvrio received approval from the FDA for treatment of amyotrophic lateral sclerosis in adults.

You May Also Be Interested In

• FDA grants priority review to AstraZeneca's efzimfotase alfa for bone disease
• Xenon files NDA for azetukalner in focal seizures, pauses psychiatry trials
• Zealand Pharma gets EU recommendation for short bowel syndrome drug